Clinical Trials Search
A Phase III Trial of Total Androgen Suppression Versus Total Androgen Suppression Plus Definitive External Beam Irradiation for Pathologic Lymph Node Positive (pN+) Adenocarcinoma of the Prostate
96-08
- Eligibility:Click Here to View1.0) Path (+) prostate ca with elevated PSA.
2.0) Path (+) pelvic lymph node involvement.
3.0) No prior chemo or RT.
4.0) No distant mets.
5.0) PSA = 4.0 is mandatory.
6.0) PS = 70 (0-1)
7.0) Orchiectomy if done, must be = 90 days prior to randomization; chemical hormones may be started prior to random. But must begin = 90 days before study entry.
8.0) Negative bone scan and CXR.
Drugs: Zoladex, Lupron Depot, Flutamide - Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.
A Phase II Study of Extended Field Radiation Following Therapeutic Para-aortic node Dissection for patients with carcinoma of the Uterine Cervix with Para-aortic Nodal Metastases
96-13
- Eligibility:Click Here to View1.0) No mets outside pelvis except para-aortic mets
2.0) PS = 70
3.0) No prior RT, Chemo, or hysterectomy - Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.
A Intermittent, Alternating Chemohormonotherapy Combined with Strontium-89 for Androgen Resistant Metastatic Prostate Carcinoma
96-2
- Eligibility:Click Here to View1.0) Path (+)prostate ca w/ clinical evidence of mets.
2.0) Evidence of hormone unresponsiveness/progres dz despite recent discont. of antiandrogen therapy.
3.0) If no evidence of bi-dimensional msble dz, then PSA must be >20
4.0)
5.0) PS 0-3
6.0) No prior chemo
7.0) Contraindication = 25% RT
Drug: Estramustine, Vinblastine, Adriamycin, Ketoconazole, Strontium-89 - Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.
A Phase II Study of LU 103793 in the Treatment of Advanced Non-Small Cell Lung Cancer
96-24-51
- Eligibility:Click Here to View1.0) Path (+) NSCLC with bidimensionally\u0009measurable dz.
2.0) Stage IIIB or IV NSCLC.
3.0) Arm A - No prior chemo for this dz allowed.
Arm B - Must have received only one previous chemo regimen for this dz and must have ended =4 weeks prior to study entry
4.0) PS 0-2
5.0) Cannot have: RT to >15% of bone marrow/RT =3 weeks.
6.0) Cannot have: CNS mets.
Drugs: LU 103793 (provided).
7.0) - Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.
A Phase II Trial of Oral Etoposide with Intravenous Paclitaxel in Patients with Refractory Metastatic Breast Cancer
96-32-54
- Eligibility:Click Here to View1.0) Path (+) breast ca w/evidence of met dz
2.0) must have had 1-2 prior chemo regimens
3.0) must have had 1 tx for met dz
4.0) No prior taxol or taxotere - Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.
A Phase II Trial of Irinotecan (CPT-11) in Patients with Refractory Metastatic Breast Cancer
96-32-55
- Eligibility:Click Here to View1.0) path (+)breast ca with evidence of progression
2.0) must have had 1 prior regimen in adjuvant setting and only 1 in metastatic setting
3.0) at least 1 prior regimen contained anthracycline or Taxane or Adria for either adjuvant or metastatic dz
4.0) life expectancy >3months - Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.
A Phase II Trial of Irinotecan in Recurrent Glioma\r
96-72-51
- Eligibility:Click Here to View1.0) Path (+)
2.0) Allowed 1 prior chemo for adj, and 1 for recurrance.
3.0) = 8 wks post RT
4.0) = 4 wks post chemo, = 6wks post nitrosourea-based chemo
Drug: CPT-11, provided.
5.0) - Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.
A Phase III Comparison of Oral Capsaicin Lozenge Versus Placebo Lozenge for Radiation-Induced-Mucositis\r\r\r
96-92-57
- Eligibility:Click Here to View1.0) Rando d1-3 of RT
2.0) No prior RT to oral mucosa, or concomitant use of chemo - Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.
A Phase II Study of Adjuvant Postoperative Irradiation Combined with Cisplatin/Taxolchemotherapy Following TAH/BSO for Patients with High-Risk Endometrial Cancer
97-08
- Eligibility:Click Here to View1.0) Grade 2 or 3 with = 50% myometrial or stromal invasion of cervix or extra uterine dz confined to pelvis
2.0) PS = 70 - Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.
A Randomized Trial of Palliative Radiation Therapy for Osseous Metastases: A Study of Palliation of Symptoms and Quality of Life
97-14
- Eligibility:Click Here to View1.0) Histo proven breast or prostate malignancy.
2.0) Radiographically evidence of bone mets w/pain at that site (mets to skull, hands and feet are not elig.).
3.0) Life expect. =3 mos.
4.0) PS = 40.
5.0) BPI score >5.
6.0) No change in systemic therapy within 30 days of random.
7.0) No prior radiotherapy or palliative surgery to the painful site.
8.0) No systemic radio-isotopes (e.g. Sr89) in past 30 days.
9.0) - Consent forms:You must be logged in to view the documents.
- Protocols:You must be logged in to view the documents.